Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma
NCT ID: NCT00044031
Last Updated: 2014-04-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
394 participants
INTERVENTIONAL
2001-02-28
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Open Label Study to Evaluate G17DT Compared to Gemcitabine
NCT03200821
Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer
NCT02118077
An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma
NCT02098291
Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.
NCT02098239
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
NCT01303172
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
B
Placebo (immunogen vehicle) combined with gemcitabine.
No interventions assigned to this group
A
500 µg G17DT immunogen combined with gemcitabine.
G17DT Immunogen
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
G17DT Immunogen
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Life expectancy of at least 3 months
* Functional status by Karnofsky Index of at least 70
Exclusion Criteria
* Chronic use of corticosteroids, except for inhaled corticosteroids used for asthma or chronic obstructive pulmonary disease
* Immunodeficiency
* Bone marrow transplant within past year
* Brain metastasis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cancer Advances Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
R Hawkins, M.D.
Role: PRINCIPAL_INVESTIGATOR
Christie Hospital, Manchester
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PC4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.